Focus Partners Advisor Solutions LLC Invests $365,000 in IQVIA Holdings Inc. $IQV

Key Points

• Focus Partners Advisor Solutions LLC acquired a new stake in IQVIA Holdings Inc., purchasing 2,069 shares valued at approximately $365,000 in the first quarter.
• Seventeen analysts have given IQVIA a Buy rating, with an average price target of $229.86, indicating strong market sentiment for the stock.
• IQVIA reported $2.81 earnings per share for the last quarter, beating estimates and highlighting a revenue increase of 5.3% compared to the same period last year.

Focus Partners Advisor Solutions LLC bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 2,069 shares of the medical research company's stock, valued at approximately $365,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. American National Bank & Trust purchased a new position in IQVIA during the first quarter worth about $26,000. Clal Insurance Enterprises Holdings Ltd raised its position in shares of IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock valued at $28,000 after buying an additional 131 shares in the last quarter. Golden State Wealth Management LLC grew its position in IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after acquiring an additional 130 shares in the last quarter. AllSquare Wealth Management LLC purchased a new position in IQVIA in the first quarter worth $33,000. Finally, ST Germain D J Co. Inc. increased its stake in IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after acquiring an additional 76 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares of the company's stock, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Redburn Partners set a $214.00 price objective on IQVIA in a report on Wednesday, September 3rd. Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Jefferies Financial Group upgraded shares of IQVIA from a "hold" rating to a "buy" rating and increased their price target for the company from $195.00 to $225.00 in a research report on Tuesday. UBS Group boosted their price objective on shares of IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Finally, Cowen reaffirmed a "buy" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Eighteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, IQVIA presently has an average rating of "Moderate Buy" and an average target price of $229.64.

IQVIA Trading Up 1.2%

Shares of NYSE IQV traded up $2.21 during trading hours on Tuesday, hitting $189.89. The company's stock had a trading volume of 1,200,874 shares, compared to its average volume of 1,916,617. The business has a 50-day simple moving average of $181.03 and a 200-day simple moving average of $167.36. The stock has a market cap of $32.28 billion, a price-to-earnings ratio of 27.48, a P/E/G ratio of 2.06 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $248.03.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The firm had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same period last year, the company earned $2.64 EPS. The business's quarterly revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.